ProHealth me-cfs Vitamin and Natural Supplement Store and Health
Home  |  Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help
Facebook Google Plus
Fibromyalgia  Chronic Fatigue Syndrome & M.E.  Lyme Disease  Natural Wellness  Supplement News  Forums  Our Story
Store     Brands   |   A-Z Index   |   Best Sellers   |   New Products   |   Deals & Specials   |   Under $10   |   SmartSavings Club

Trending News

Beginning Again: Living with the Ups and Downs of Life with Chronic Illness

Chronic Christmas: Surviving the Holidays with a Chronic Illness

Productivity Values That Get in the Way of Our Health

Happiness, Gratitude and Appreciation

The “Starvation” Disease? Metabolomics Meets Chronic Fatigue Syndrome Down Under

Vital Molecule Increases Cellular Energy and Improves Cognitive Function

The IACFS/ME 2016 Conference Overviews #1: Energy and Exercise To the Fore

Is Chronic Fatigue Syndrome An Inflammatory Disease? The 2016 IACFS/ME Conference Overviews Pt II

Psychotherapy for ME/CFS Does Not Help Fatigue (much)

Medscape Rocks the IACFS/ME Conference

 
Print Page
Email Article

Mainstreaming ME Research: The 8th Invest in ME International ME Conference, 2013

  [ 5 votes ]   [ Discuss This Article ]
By Mark Berry • www.ProHealth.com • August 7, 2013


SourcePhoenix Rising, June 2, 2013

By Mark Berry

The presentations you’re about to read about are only half the story; the opportunity to mingle and network with a family of top researchers, physicians, campaigners and patients from all over the world, is absolutely priceless. And this year, the new spirit of hope and togetherness in the air was a joy to behold.

The title this year was “Mainstreaming ME Research: Infections, Immunity and Myalgic Encephalomyelitis”, and the twin themes – an emerging consensus around a ‘paradigm shift’ to thinking about ME as an autoimmune disorder, and a focus on strategies for effective research and a breakthrough into the scientific mainstream – fit together perfectly. For it’s the growing recognition that immune treatments like Rituximab and Ampligen are having dramatic effects on many patients who were once bedbound and without hope, together with two decades of often confusing but highly suggestive research findings of immune dysfunction in ME patients, that is now threatening to propel ME from the backwaters of science right into the limelight.

A key part of that process has been Invest in ME’s Clinical Autoimmunity Working Group, formed last year – a group of researchers which meets before the main conference to discuss the latest scientific developments. The creation of international collaborative networks is surely valuable in any field of science, but in a field that has been so neglected and so under-resourced for so long, it’s even more important to maximize resources.

Once the working group has done its thing, next comes the pre-conference dinner – the Patient Advocate reports on Linda Tannenbaum’s pre-conference dinner presentation here.

And then it’s on with the main event: time for conference-goers to pick up their copy of the Conference Journal, mingle and chat with old friends over coffee for a while, and settle down for the first item on the Agenda.

Conference Highlights

  • Dr Ian Gibson announces new PhD studentship in Norwich looking at gut bacteria. “Things are beginning to pop, across the nation and across the world…There’s a new spirit loose, I think, in the ME field”.
  • Dr Peterson keynote: “It’s time to stop querying patients and begin developing new diagnostics”. We need both clear endpoints and clear populations for successful research.
  • Dr Kogelnik: Medicine is at a crossroads, and ME will be “key disease” in coming “health/disease revolution”: technology enables the ‘Quantified Self’ and personalized medicine. Govt agencies “not the enemy”, it’s “their ignorance and our lack of data” – our job is to bring them the data so it can’t be ignored.
  • Dr Rakib Rayhan: In Gulf War Illness, Baraniuk et al believe their brain scans after exercise challenge produced a “quite robust biomarker”, and they want to extend to ME/CFS. New study out in a couple of weeks finds 2 subgroups for pain and fatigue post-exercise.
  • Professor Greg Towers puts XMRV saga to bed: valuable lessons learned mean this kind of situation should never happen again.
  • Professor Mady Hornig: Final analysis of cerebrospinal fluid now underway; possible finding of ‘different patterns of cytokine associative networks’ and ‘potential novel candidate’ in CSF still needs to be confirmed.
  • Dr Clare Gerada steps into the lions’ den and “tells it straight” – attempts to “build a bridge between the largest Royal College and a very important problem” – hopes to “be better able to work with you to improve the care you receive from my profession”.
  • Dr Donald Staines stands in for Professor Sonya Marshall-Gradisnik. Publications expected in next weeks and months; still finding “sustained, demonstrable, significant impairment in NK cell function”, “highly confident” of up-regulation of T-reg cells; “clear derangement in the immune system…it’s irrefutable”, and “anyone who suggests that this might be fixed by exercise therapy should probably be de-registered I think”.
  • Dr Amolak Bansal senses a “paradigm shift” towards model of subtle form of autoimmunity in ME; suspects patients’ B cells are failing to mature properly and producing low avidity antibodies; lasting response to B-cell depletion therapy may require clearing the viruses responsible in addition to ‘rebooting’ the B cells.
  • Norwegian ME Association presents awards to Invest in ME founders Richard and Pia Simpson, and to Professor Malcolm Hooper for “untiring and exceptional contribution to the ME cause”. Hooper accepts with his shortest ever speech.
  • Carmen Scheibenbogen and her team at Charite are finding similar immune dysfunction and share many of the same theories as Bansal, Fluge and Mella. They’re trying to develop a diagnostic test, investigating EBV infections in depth, and seeing 3 immune subtypes of CFS, hoping for solid data in about 6 months.
  • Professor Mella and Dr Fluge are closing in on publication of their follow-up study on Rituximab therapy. Some details were presented, along with a fascinating hypothesis, but that’s all embargoed awaiting publication.

Read the rest of this article here.




Post a Comment

Featured Products From the ProHealth Store
B-12 Extreme™ Mitochondria Ignite™ with NT Factor® Energy NADH™ 12.5mg


Article Comments



Be the first to comment on this article!

Post a Comment


 
Natural Pain Relief Supplements

Featured Products

Ultra ATP+, Double Strength Ultra ATP+, Double Strength
Get energized with malic acid & magnesium
B-12 Extreme™ B-12 Extreme™
The Most Potent Vitamin B-12 on Earth
Hydroxocobalamin Extreme™ Hydroxocobalamin Extreme™
The B-12 Your Brain Needs for Detox & Sharpness
MitoQ® MitoQ®
Powerful Antioxidant Support to Mitochondria
Energy NADH™ 12.5mg Energy NADH™ 12.5mg
Improve Energy & Cognitive Function

Natural Remedies

Sleep Like a Baby in Nature's Cradle Sleep Like a Baby in Nature's Cradle
Enhance Eyelashes Naturally Enhance Eyelashes Naturally
Breaking Through the Mental Fog Breaking Through the Mental Fog
The Big Blue Fish that Helps Chase the Blues Away The Big Blue Fish that Helps Chase the Blues Away
Eating Fat is Good... Maybe... Could Be... Sometimes Eating Fat is Good... Maybe... Could Be... Sometimes

CONTACT US
ProHealth, Inc.
555 Maple Ave
Carpinteria, CA 93013
(800) 366-6056  |  Email

· Become a Wholesaler
· Vendor Inquiries
· Affiliate Program
SHOP WITH CONFIDENCE
Credit Card Processing
SUBSCRIBE TO OUR NEWSLETTERS
Get the latest news about Fibromyalgia, M.E/Chronic Fatigue Syndrome, Lyme Disease and Natural Wellness

CONNECT WITH US ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus

© 2016 ProHealth, Inc. All rights reserved. Pain Tracker App  |  Store  |  Customer Service  |  Guarantee  |  Privacy  |  Contact Us  |  Library  |  RSS  |  Site Map